Skip to main content
OpenTrials
Completed

NCT Number: NCT00418301

Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain

The primary objective of this study is to identify the brain regions in which activity is affected by SCS. Baseline cerebral blood flow scans with the device turned off will be generated compared to scans produced with the device operating at parameters which produce optimal coverage of the painful areas. The relationship between cerebral blood flow and pain rating scores will be evaluated in both conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Clinical Research

Winston-Salem, North Carolina, 27103, United States

About this study

Spinal Cord Stimulation (SCS) is known to be effective in pain management. Some evidence exists that SCS may cause changes in cerebral blood flow. This study will be a novel PET examination of activity in brain regions affected by SCS. This activity will be compared with the pain intensity and distribution. Further, by examining cerebral blood flow at different doses of stimulation, relationships between SCS, brain perfusion, and pain relief can be drawn. This study will contribute to the elucidation of the mechanism of action of SCS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have had one or more back surgery procedures.
  • Have used an active Precision SCS device for chronic low back and bilateral leg pain for at least 6 weeks.
  • Have bilateral leg pain.
  • Have a baseline VAS of >4 (without stimulation).
  • Have greater than 50% reduction in pain with SCS at optimal settings
  • Be 18 years of age or older.
  • Have the cognitive and functional capability to operate the controls for the device, to comply with directions during the study, and willing to participate in all study activities.
  • Be capable of reading and understanding patient information materials and giving written informed consent.

Exclusion criteria

  • Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints.
  • Have undergone a surgical lead revision or had any Precision components replaced after initial implantation.
  • Are allergic to any of the injected media.
  • Are pregnant or lactating.
  • Have any contraindication to the PET scan procedure itself or exposure to the intravenous radioactive tracer (H215O).
  • Have participated in any drug or device trial in the last 4 weeks or are currently participating in another drug or device trial.

Treatment and study plan

Precision Spinal Cord Stimulation and PET Scan

Other

Imaging procedure to assess spinal Cord Stimulation.

Primary outcomes

  1. Cerebral Blood Flow and VAS With Optimal Paresthesia Coverage Compared With SCS Off

    Time frame: Within a few hours

Secondary outcomes

  1. Cerebral Blood Flow and VAS With Partial Paresthesia Coverage and Subthreshold Stimulation Compared With Optimal Coverage and With SCS Off

    Time frame: Within a few hours

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Changes in Regional Cerebral Blood Flow as an Indicator of Neuronal Activity in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jan 4, 2007
Registry last updated
Mar 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.